BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, derived from part of a protective protein found in human gastric juice. In animal studies — overwhelmingly in rats — it appears to accelerate healing across several tissue types: tendons, the gut lining, muscle, bone and nerve ^[5]. The most consistent explanation researchers put forward is that it prompts the body to grow new blood vessels into an injury site, bringing the oxygen and nutrients that repair demands ^[4].

Here is the honest accounting. Almost all of this evidence is in animals. As of 2025, only three small human pilot studies of BPC-157 exist, and no large, rigorous controlled trials have been completed ^[2]. BPC-157 is not an approved drug anywhere. It is prohibited in sport. Popular claims about weight loss, muscle gain or testosterone are not supported by the published literature ^[2]. This page summarizes what was studied; it does not advise on use and lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" means a peptide of fifteen amino acids, and "stable gastric" signals both that the sequence originates from a cytoprotective protein in gastric juice and that it resists breakdown in stomach acid. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular formula C62H98N16O22. It is also catalogued in the literature under the research designations PL 14736, PLD-116, PL-10, and Bepecin. BPC-157 is a synthetic research peptide — not extracted from a natural source, not a hormone, and not an approved drug or dietary supplement.

How it works

The best-documented mechanism is angiogenesis — the formation of new blood vessels into tissue that needs repair. A 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells showed that BPC-157 up-regulated the expression of VEGFR2 (a key vessel-growth receptor) and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway; blocking that internalization blocked the effect ^[4]. In plain terms: BPC-157 appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in an ischemic muscle model in the same experiments ^[4].

Beyond angiogenesis, the literature describes additional reported routes — FAK-paxillin cell-migration signaling, sensitization of the growth-hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide system and several neurotransmitter pathways ^[4]. The picture is of a peptide that nudges several repair-relevant processes at once rather than hitting a single clean target.

What the research shows

Foundational cytoprotection. The compound's name is rooted in gut biology. In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric, and ulcer-formation inhibition ratios of roughly 46-66% at higher doses ^[5].

Pharmacokinetics. The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life under 30 minutes, modest intramuscular bioavailability (approximately 14-19% in rats and 45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism ^[3]. A short half-life means the intact peptide clears the bloodstream quickly after dosing.

Angiogenesis in vivo. The 2017 VEGFR2 study demonstrated increased vessel density in both chick and rat models and accelerated blood-flow recovery in ischemic muscle — with the mechanism traced to VEGFR2 internalization and downstream Akt-eNOS activation ^[4].

Human evidence. It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. Two people in a safety pilot is not efficacy evidence. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational ^[2].

Reported effects, cautions & safety

The safety picture within the tiny human dataset and the animal work is reassuring as far as it reaches — but "as far as it reaches" is the operative phrase. The absence of long-term, large-sample human safety data means the real-world safety profile is genuinely unknown ^[2].

Several cautions follow directly from the peer-reviewed record:

• Overwhelmingly preclinical evidence. Most of what is reported comes from rodents, and a significant portion of the foundational literature originates from a single research group — a replication gap that newer authors explicitly flag ^[2].
• Unregulated supply. BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, meaning product identity, purity and actual dose are unverified outside formal studies.
• Banned in sport. WADA prohibits BPC-157 at all times under the S0 non-approved-substances category — a direct concern for competitive athletes.
• Unsubstantiated claims. Common online assertions — weight loss, muscle building, testosterone increases — are not supported by the published evidence and should be treated skeptically ^[2].
• Three human pilots. The safety reassurance from animal and pilot data is real but narrow; without large, controlled human trials, the benefit-risk profile in people remains open.

Where it fits in recovery research

BPC-157 is the lead compound on this desk, and the more broadly studied of the two. Its animal record spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward story — new vessels as the common engine of repair across tissue types. Its human file is three small pilots ^[2]. Alongside KPV, which approaches healing from the inflammation side, BPC-157 represents the supply-and-structure angle: bringing blood vessels in, not quieting signals down. See the comparison page for how they line up.